Agilent
Agilent Technologies Nabs IVDR Certification for PD-L1 CDx
The PD-L1 IHC 28-8 PharmDx test is used to provide information on PD-L1 expression as a biomarker for patient response to therapies containing anti-PD-1 antibodies.
FDA Approves Adaptimmune's TCR Therapy Tecelra for Certain Synovial Sarcoma Patients
The accelerated approval marks the first time the FDA has approved an engineered autologous cell therapy for a solid tumor indication.
Agilent, Incyte Ink Companion Diagnostic Development Pact for Hematology, Oncology
Under the deal, Agilent will expand its portfolio of novel biomarkers and potentially register and commercialize assays developed in the agreement.
Agilent Gets FDA Approval of Expanded Use of CDx Assay for Keytruda
The firm said it secured agency approval for its PD-L1 IHC 22C3 PharmDx test to guide treatment of patients with gastric or GEJ adenocarcinoma.
The firm is expanding its lab capabilities and leveraging its test development reputation to form partnerships early in the drug development process.